BriaCell presents positive Bria-IMT data at AACR; 15/18 alive, immune activation in anergic patients

BriaCell Therapeutics Corp.

15 of 18 patients enrolled since 2021 remain alive; survival compares favorably to 6.7-9.8 months in similar studies.
PFS benefit: most patients had PFS similar or higher than prior therapy, suggesting better tolerability and clinical effectiveness.
Immune activation in 70% of anergic patients (weak immune systems) and 89% of non-anergic after Bria-IMT combo.
8 of 17 HR+ patients (large segment) experienced PFS benefit; no immunotherapies shown to work in HR+ breast cancer.
Next-gen Bria-OTS2.0 significantly more effective than Bria-OTS in activating naïve T-cells; planned for Phase I/IIa.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.